Hyloris Developments
ActiveSummary
The annual accounts of Hyloris Developments for financial year 2025 show a net loss of 164% of the equity at the start of that year. The 2025 annual accounts show equity of €17.9m and a net result of -€5.3m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 89% of 88 sector peers (NACE 21, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.5% (very low).
Directors
Statutory auditor 1
Mandate history
- Statutory auditor
| Name | Functions and periods |
|---|---|
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES |
|
Owners and capital
Owners
1 ownerChain of control
- Hyloris Pharmaceuticals
- Hyloris Developments
Highest known parent: Hyloris Pharmaceuticals. The sources do not say who stands above it.
Owners 1
-
100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.